This dependence highlights a crucial need to be aware that not every figure in the accounts and not every word in the notes can be taken at face value. There are certain facts to be kept in mind for safeguarding the investors’ interests.

In terms of financial performance, the company expects its revenue (in USD terms) for the current quarter to decline sequentially up to a low double-digit percentage, with a consequent lower EBIT margin as compared to that reported for Q4FY20

The market opened in the green on June 22, 2020. The previous trading session witnessed the Sensex going up 523.68 points to end at 34,731.73 and the Nifty was up 152.75 points to close at 10,244.40 .

The market opened in the green on June 22, 2020. The previous trading session witnessed the Sensex going up 523.68 points to end at 34,731.73 and the Nifty was up 152.75 points to close at 10,244.40 .

The market opened in the green on June 22, 2020, overall volumes in futures & options currently stand at 1.90 crore contracts with a turnover of Rs. 11,06,171.96 crore.
 

The market opened in the green on June 22, 2020, overall volumes in futures & options currently stand at 1.90 crore contracts with a turnover of Rs. 11,06,171.96 crore.

Glenmark has received permission from Indian drug regulator to manufacture and market Favipiravir introduced as ‘Fabiflu’, the first oral anti-viral treatment option for mild to moderate COVID-19 patients in India.

Cipla Limited today announced the launch of Remdesivir under its brand name CIPREMI. United States Food and Drug Administration (USFDA) issued an emergency use authorisation (EUA) to Gilead Sciences Inc. for emergency use of the drug for the treatment of COVID-19 patients.

Including the latest ANDA approval, the company has a total of 124 ANDA approvals, of which, 110 are at the final stage and 14 have been granted tentative approvals by United States Food and Drug Administration (USFDA).

Biocon Ltd today announced that Biocon’s subsidiary, Biocon Pharma Limited and DKSH Business Unit Healthcare, have signed an agreement under which DKSH will sell and distribute seven of Biocon Pharma’s generic formulations in Singapore and Thailand.